Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline versus moxifloxacin for adults with community-acquired bacterial pneumonia
2020-002986-32Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community acquired pneumonia (CAP) comparing Omadacycline IV to oral with Moxifloxacin IV to oral (2 arms). Primary endpoint: Early Clinical Response success. Started Oct 2020; status: completed.
02
Drugs
omadacyclinemoxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2020-002986-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002986-32.